Vemurafenib Terminated Phase 1 Trials for Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor / V600-mutated BRAF Metastatic Melanoma / V600-mutated BRAF Unresectable Melanoma Treatment

TerminatedTreatment1 IdentifierTitleDrugs
NCT01826448A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma